Skip to content
DraconiticResearch
Search Sources API
194,067 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC-NDLeukemia research reports

CD20 antibody-based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma.

  • Yajun Zhang1
  • Wanqian Hu1
  • Ying Fang1
  • Bo Zheng1
  • Yi Zhang1
  • Wenda Chen1
  • Rong Li1
  1. 1Nuclear Radiation Injury Protection and Treatment Department, Navy Medical Center of PLA, Shanghai, 200050, China.
Read full textPDFDOICite

Abstract

Background

Monoclonal M-protein is frequently detected in marginal zone lymphoma (MZL) and has been historically associated with adverse clinical features. Its prognostic value in the era of modern immunotherapy remains unclear.Patients and methods

We retrospectively analyzed 43 patients with MZL, comparing clinical characteristics, treatments, and outcomes between patients with and without M-protein. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier analysis, and prognostic factors were evaluated by Cox regression.Results

M-protein was detected in 39.5% of patients and was associated with higher tumor burden, worse performance status, and elevated inflammatory and biochemical markers. However, no significant differences in PFS or OS were observed between groups, and M-protein was not an independent prognostic factor. Most patients received contemporary CD20 antibody-based combination therapies.Conclusion

In the setting of modern treatments, M-protein positivity may not confer an adverse prognostic impact in MZL.

Related

  1. CD10-Positive Extranodal Marginal Zone Lymphoma of the Thyroid Arising in Hashimoto’s Thyroiditis: A Rare Diagnostic Challenge
    Narmeen Giacaman, Lena Nemri, Rodolfo Henrich Lobo +1
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Ocular Follicular Lymphoma with Marginal Zone Differentiation: A Diagnostic Pitfall Mimicking MALT Lymphoma
    Takashi Miyachi, Akihiro Kitadate, Wataru Kuroki +3
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  3. Real-World Treatment Patterns, Healthcare Resource Use, and Costs in Patients with Follicular Lymphoma, Waldenström Macroglobulinemia, and Marginal Zone Lymphoma: A Claims-Based Study in the USA
    Mahek Garg, Ambika Satija, Yan Song +3
    Clinical Drug InvestigationPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  4. Recent advances in function-enhanced antibody-drug conjugates: Antibody optimization and payload combination
    Xin-tong Liu, Feng Tang, Wei Huang
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text1 citedMedical imaging & radiologyPMC
  5. Longitudinal single-cell and spatial transcriptomics reveals intratumor heterogeneity, therapeutic response, and comparative value of canine marginal zone lymphoma
    G. E. Walker, M. Macchietto, K. Reid +18
    bioRxivPreprintCC BYFull textOncologybioRxiv

Cite

BibTeXRIS
BibTeX
@article{zhang2026cd20,
  title = {{CD20 antibody-based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma.}},
  author = {Yajun Zhang and Wanqian Hu and Ying Fang and Bo Zheng and Yi Zhang and Wenda Chen and Rong Li},
  journal = {Leukemia research reports},
  year = {2026},
  month = oct,
  doi = {10.1016/j.lrr.2026.100616},
  url = {https://europepmc.org/article/MED/42921349},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - CD20 antibody-based combination therapy may reduces the adverse prognostic impact of M-protein positivity in marginal zone lymphoma.
AU  - Yajun Zhang
AU  - Wanqian Hu
AU  - Ying Fang
AU  - Bo Zheng
AU  - Yi Zhang
AU  - Wenda Chen
AU  - Rong Li
PY  - 2026
DA  - 2026/10/09
JO  - Leukemia research reports
DO  - 10.1016/j.lrr.2026.100616
UR  - https://europepmc.org/article/MED/42921349
AB  - Background  Monoclonal M-protein is frequently detected in marginal zone lymphoma (MZL) and has been historically associated with adverse clinical features. Its prognostic value in the era of modern immunotherapy remains unclear.Patients and methods  We retrospectively analyzed 43 patients with MZL, comparing clinical characteristics, treatments, and outcomes between patients with and without M-protein. Progression-free survival (PFS) and overall survival (OS) were assessed using Kaplan-Meier analysis, and prognostic factors were evaluated by Cox regression.Results  M-protein was detected in 39.5% of patients and was associated with higher tumor burden, worse performance status, and elevated inflammatory and biochemical markers. However, no significant differences in PFS or OS were observed between groups, and M-protein was not an independent prognostic factor. Most patients received contemporary CD20 antibody-based combination therapies.Conclusion  In the setting of modern treatments, M-protein positivity may not confer an adverse prognostic impact in MZL.
SN  - 2213-0489
ER  -